Market research
SYNGENE.NSE Syngene International Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 147B
- P/E ratio
- 66.7
- Analyst target
- 493.125
- Dividend yield
- 0.0%
- Beta
- 0.07
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- INE398R01022
- Market cap
- 147B
- P/E ratio
- 66.7
- Analyst target
- 493.125
- Dividend yield
- 0.0%
- Beta
- 0.07
About
About Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Research context
Syngene International Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SYNGENE.NSE discussion.
5 years, 6 months ago
Syngene International Limited is currently in a long term uptrend where the price is trading 1.9% above its 200 day moving average.
From a valuation standpoint, the stock is 136.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.3.
Syngene International Limited's total revenue rose by 12.6% to $6B since the same quarter in the previous year.
Its net income has increased by 11.3% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 30.0% to $1B since the same quarter in the previous year.
Based on the above factors, Syngene International Limited gets an overall score of 3/5.